CD8A and neoplasm: Targeting JAK/STAT3 signaling holds considerable promise for inhibiting the immunosuppressive function of neutrophils.483 Cabozantinib, a tyrosine kinase inhibitor, significantly reduces neutrophil infiltration in the tumor microenvironment and its immunosuppressive activity on CD8+ and CD4+ T cells.753 A phase I clinical trial (NCT05038839) is evaluating the efficacy of cabozantinib in combination with pamipanib for advanced refractory solid tumors.